Dyne Therapeutics, Inc. (DYN) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Dyne Therapeutics, Inc. (DYN) Bundle
Enhance your investment strategies with the Dyne Therapeutics, Inc. (DYN) DCF Calculator! Review the latest financial data, adjust growth projections and expenses, and instantly observe how these modifications affect the intrinsic value of Dyne Therapeutics, Inc. (DYN).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -14.6 | -58.3 | -148.2 | -164.8 | -233.5 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .3 | .7 | 1.1 | 3.3 | 2.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -14.9 | -59.0 | -149.3 | -168.1 | -235.9 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 14.6 | 345.3 | 376.6 | 256.0 | 123.1 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.3 | 3.4 | 4.0 | 5.3 | 22.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -1.6 | -1.2 | -3.6 | -3.1 | -.7 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -13.5 | -58.3 | -149.3 | -165.2 | -235.9 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -13.7 | -56.6 | -151.2 | -163.7 | -216.5 | -22.9 | .0 | .0 | .0 | .0 |
| WACC, % | 9.51 | 9.52 | 9.52 | 9.52 | 9.52 | 9.52 | 9.52 | 9.52 | 9.52 | 9.52 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -20.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -21 | |||||||||
| Net Debt | -94 | |||||||||
| Equity Value | 73 | |||||||||
| Diluted Shares Outstanding, MM | 60 | |||||||||
| Equity Value Per Share | 1.23 |
What You Will Get
- Real DYN Financials: Access to both historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures to fit your analysis.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Dyne Therapeutics' future performance.
- User-Friendly Design: Designed for professionals while remaining accessible to newcomers.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, revenue forecasts, and R&D expenditures.
- Instant Valuation Insights: Automatically computes intrinsic value, NPV, and other financial metrics in real-time.
- High-Precision Analytics: Leverages Dyne Therapeutics’ actual financial data for accurate valuation results.
- Streamlined Scenario Testing: Easily explore various assumptions and evaluate different outcomes.
- Efficiency Booster: Remove the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Dyne Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Dyne Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Dyne Therapeutics, Inc. (DYN)?
- Accurate Data: Utilize real Dyne Therapeutics financial data for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth projections, WACC, and tax rates to fit your specific needs.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear step-by-step guidance make it accessible for everyone.
Who Should Use Dyne Therapeutics, Inc. (DYN)?
- Individual Investors: Gain insights to make informed decisions about investing in Dyne Therapeutics.
- Financial Analysts: Enhance your analysis with comprehensive financial models tailored for Dyne Therapeutics.
- Consultants: Provide clients with expert valuation insights related to Dyne Therapeutics efficiently and effectively.
- Business Owners: Learn from Dyne Therapeutics' valuation to inform your own business strategies.
- Finance Students: Explore valuation methodologies using real data from Dyne Therapeutics for practical learning.
What the Template Contains
- Pre-Filled DCF Model: Dyne Therapeutics, Inc. (DYN)’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Dyne Therapeutics, Inc. (DYN)’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.